You are viewing an old version of this page. View the current version.

Compare with Current View Page History

« Previous Version 14 Next »

Summary

This collection combines advanced molecular imaging treatment response assessment through pre- and post-treatment FDG PET/CT scans with therapy of advanced head and neck cancer, including chemo-radiation therapy with and without addition of an EGFR inhibitor
molecular targeted agent (Cetuximab). 

The Head-Neck Cetuximab collection consists of a subset of image data from RTOG 0522/ACRIN 4500, which was randomized phase III Trial of Radiation Therapy and Chemotherapy for stage III and IV Head and Neck carcinomas. The RTOG 0522/ACRIN 4500 protocols were activated in November 2005 and successfully completed accrual of 945 patients in 2009. As part of the RTOG 0522 trial, institutions had the option to join the RTOG 0522/ACRIN 4500 imaging study. The post-treatment FDG PET/CT scan was performed 8-9 weeks after completion of treatment before any nodal dissection.  For this reason the data was provided through two independent channels:

  • RTOG 0522: CT, Structures, RT Doses, RT Plans sent to ITC
  • ACRIN 4500: Quantitative PET (PET/CT) sent to ACRIN

For more information about the original aims of this trial please see: http://meeting.ascopubs.org/cgi/content/abstract/29/15_suppl/5500.

Data Access

Imaging Data

You can view and download these images on TCIA by clicking and selecting the Head-Neck Cetuximab collection.

Collection Statistics

Updated 11/14/2013

Modalities

PT, CT, RTSTRUCT, RTDOSE, RTPLAN

Number of Patients

111

Number of Studies

368

Number of Series

1,682

Number of Images

202,574

Image Size (GB)48.8

If you are unsure how to download this Collection please view our quick guide on Searching by Collection or refer to our The Cancer Imaging Archive User's Guide for more detailed instructions on using the site.

Shared Lists

  • None available at this time

Note: See Section 3.7 of TCIA User Guide for help with Shared Lists.

Supporting Documentation and metadata

Please note that 10 cases in this collection do not contain RT data.  Eight cases whose RT QA scores that were not "Per Protocol" or "Variation Acceptable" were excluded:  96, 133, 141, 143, 154, 182, 475, 478.  Also, subject 243 was ineligible and subject 260 expired prior to follow-up.

  • No labels